WO2010097501A3 - A combination treatment of stroke - Google Patents

A combination treatment of stroke Download PDF

Info

Publication number
WO2010097501A3
WO2010097501A3 PCT/FI2010/000014 FI2010000014W WO2010097501A3 WO 2010097501 A3 WO2010097501 A3 WO 2010097501A3 FI 2010000014 W FI2010000014 W FI 2010000014W WO 2010097501 A3 WO2010097501 A3 WO 2010097501A3
Authority
WO
WIPO (PCT)
Prior art keywords
stroke
inhibitor
angiotensin
combination treatment
ace
Prior art date
Application number
PCT/FI2010/000014
Other languages
French (fr)
Other versions
WO2010097501A2 (en
Inventor
Jukka Sallinen
Mikko KUOPPAMÄKI
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of WO2010097501A2 publication Critical patent/WO2010097501A2/en
Publication of WO2010097501A3 publication Critical patent/WO2010097501A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A combination of a PDE III inhibitor and an angiotensin II receptor antagonist or an angiotensin converting enzyme (ACE) inhibitor shows synergistic effect in the prevention of stroke. Pharmaceutical compositions and medical kits comprising as a first active ingredient a PDE III inhibitor and as a second active ingredient an angiotensin II receptor antagonist or an angiotensin converting enzyme (ACE) inhibitor are provided.
PCT/FI2010/000014 2009-02-26 2010-02-25 A combination treatment WO2010097501A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15573809P 2009-02-26 2009-02-26
US61/155,738 2009-02-26

Publications (2)

Publication Number Publication Date
WO2010097501A2 WO2010097501A2 (en) 2010-09-02
WO2010097501A3 true WO2010097501A3 (en) 2010-11-18

Family

ID=42312874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2010/000014 WO2010097501A2 (en) 2009-02-26 2010-02-25 A combination treatment

Country Status (1)

Country Link
WO (1) WO2010097501A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656412T3 (en) 2011-12-21 2018-02-27 Elanco Tiergesundheit Ag New combination
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
WO2013135853A1 (en) * 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical packaging product for the veterinary medical sector
CN106214680B (en) * 2016-07-29 2018-05-11 珠海赛隆药业股份有限公司（长沙）医药研发中心 A kind of compound of angiotensin receptor antagonist and Levosimendan and application thereof
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071385A2 (en) * 2003-02-13 2004-08-26 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
WO2005107757A2 (en) * 2004-05-12 2005-11-17 Orion Corporation A method for the prevention of thromboembolic disorders
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071385A2 (en) * 2003-02-13 2004-08-26 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
WO2005107757A2 (en) * 2004-05-12 2005-11-17 Orion Corporation A method for the prevention of thromboembolic disorders
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PADMA VASAMTHA ET AL: "Antihypertensive medications for risk reduction of first and recurrent ischemic stroke", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, FUTURE DRUGS, LONDON, GB LNKD- DOI:10.1586/14779072.2.6.867, vol. 2, no. 6, 1 November 2004 (2004-11-01), pages 867 - 876, XP009109884, ISSN: 1477-9072 *
PREVENTION STUDY GROUP GOTOH ET AL: "Design and organization of the cilostazol stroke prevention study", JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES, DEMOS PUBLICATIONS, NEW YORK, NY, US LNKD- DOI:10.1016/S1052-3057(00)38264-7, vol. 9, no. 1, 1 February 2000 (2000-02-01), pages 36 - 44, XP022292163, ISSN: 1052-3057 *
SCHRADER JOACHIM ET AL: "Inhibition of the renin-angiotensin system and the prevention of stroke", AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, ADIS INTERNATIONAL, NZ LNKD- DOI:10.2165/00129784-200707010-00003, vol. 7, no. 1, 1 January 2007 (2007-01-01), pages 25 - 37, XP009109888, ISSN: 1175-3277 *

Also Published As

Publication number Publication date
WO2010097501A2 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
MY146969A (en) Dpp iv inhibitor formulations
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2012027065A3 (en) Combination therapy for treatment of disease
WO2011002808A8 (en) Hcv protease inhibitors and uses thereof
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2011039367A3 (en) Pharmaceutical compositions comprising bi-1356 and metformin
WO2009089494A3 (en) Pharmaceutical compositions
MX2010014041A (en) A crystalline form of posaconazole.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2010097501A3 (en) A combination treatment of stroke
EP2351753A4 (en) Phenanthroindolizidine derivative and nf b inhibitor containing same as active ingredient
WO2012084423A3 (en) Active ingredient combinations of glyceryl glucosides and one or more mild surfactants
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
EP2351754A4 (en) Phenanthroindolizidine compound and nf b inhibitor containing same as active ingredient
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
JO3587B1 (en) Oral dosage forms of bendamustine
ZA200904346B (en) Synergistic active ingredient combination
WO2009124103A3 (en) Combination therapies comprising par1 antagonists with par4 antagonists
MX346316B (en) Pharmaceutical or neutraceutical formulation.
EP2351748A4 (en) Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
TR201803451T4 (en) OLMESARTAN FORMULATIONS.
WO2012084418A3 (en) Active ingredient combinations of glyceryl glucosides and one or more acidic preservatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722150

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10722150

Country of ref document: EP

Kind code of ref document: A2